We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

By LabMedica International staff writers
Posted on 14 May 2026

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options. More...

Hospitals are increasingly facing high-risk lineages and mobile carbapenemase genes that can accelerate transmission across healthcare settings and borders. Robust genomic surveillance can help track this spread and inform coordinated responses. New findings now present a Europe-wide genomic survey of carbapenem- and/or colistin-resistant Enterobacterales in clinical settings.

The European Centre for Disease Prevention and Control (ECDC) coordinated the Carbapenem- and/or Colistin-Resistant Enterobacterales (CCRE) survey, an integrated genomic surveillance initiative. The program combines epidemiological and microbiological inputs with whole-genome sequencing to delineate circulating lineages and resistance determinants across hospitals. By structuring data collection and analysis at continental scale, it advances routine use of genome-based methods for AMR surveillance.

Conducted in collaboration with the Public Health Agency of Sweden and The Centre for Genomic Pathogen Surveillance, Pandemic Sciences Institute, University of Oxford, the survey aggregated 2019 data from more than 300 hospitals in 36 countries. It is the second large-scale structured genomic effort following the European Survey of Carbapenemase-producing Enterobacteriaceae (EuSCAPE) in 2013–2014, marking a shift toward integrated Europe-wide genomic surveillance. Beyond sampling, participating countries underwent capacity assessments, training, and external quality assurance exercises to embed genomic workflows in national reference laboratories.

For Klebsiella pneumoniae, carbapenem-resistant high-risk lineages identified during EuSCAPE persisted across hospitals. The survey also documented increased acquisition of carbapenemase genes by high-risk K. pneumoniae lineages, expansion of newly emerging high-risk lineages, and wider spread of isolates carrying virulence genes. 

For Escherichia coli, warning signals included more frequent acquisition of carbapenemase genes by high-risk sequence types, greater clonal spread of successful multidrug-resistant lineages, and increased detection of isolates harboring the NDM-5 carbapenemase gene. The findings depict heterogeneous country-level patterns, ranging from sporadic cases to endemic circulation, and indicate a high risk that carbapenem-resistant E. coli could become endemic without additional public health action.

Results were published in The Lancet Microbe in separate articles on K. pneumoniae and E. coli, accompanied by a detailed ECDC report. The CCRE dataset provides reference information to guide further investigations of carbapenem-resistant Enterobacterales and to inform public health action. Data collection for the third European Survey of carbapenem-resistant Enterobacterales (CRE25) is underway, using a simplified sampling protocol and faster reporting enabled by increased whole-genome sequencing capacity at national reference laboratories.

Related Links
European Centre for Disease Prevention and Control 


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
New
HPV Test
Allplex HPV28 Detection
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.